San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Neurelis is raising $42,098,007.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Craig Chambliss played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neurelis

Neurelis is a neuroscience-based specialty pharmaceutical company with a unique portfolio of product candidates and innovative platform technologies. Along with our strategic partners, we are dedicated to enhancing therapeutic benefits and addressing significant unmet needs in patient care. Neurelis was founded to license, develop, and commercialize product candidates for the broader central nervous system (CNS), including epilepsy and psychiatry. Our emphasis is on highly differentiated therapies that empower patients, care partners, and healthcare providers. The benefits of our unique platform technology allow us to form strategic partnerships to address significant unmet needs in other therapeutic areas as well.

To learn more about Neurelis, visit http://www.neurelis.com/

Contact:
Craig Chambliss, Chief Executive Officer
858-251-2100
cchambliss@neurelis.com
https://www.linkedin.com/in/craigchambliss/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved